Archive for April 2019
Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Targeted therapy for cancer is based on personalized medicine approach SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office. About Tozaride Tozaride is…
Read MoreAndarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference
Targeted therapy for breast cancer is based on personalized medicine approach SOMERVILLE, MA — April 24, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address…
Read More